Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXi4503 in R/R AML and MDS
NCT02576301Phase 2Unknown
- Sponsor
- Oncotelic Therapeutics, Inc.
- Start
- Oct 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxi-4503 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Oncotelic Therapeutics, Inc.. Status: unknown.
02
Drugs
oxi-4503
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02576301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576301.